Preliminary Pharmacokinetic Analysis of Tramadol and Its Metabolite O-Desmethyltramadol in Boa (Boa constrictor constrictor)
Authors:
- Marina Lopes CastroMCMarina Lopes Castro
- Natalya Maldonado MorenoNMNatalya Maldonado Moreno
- Raphael Rocha WenceslauRWRaphael Rocha Wenceslau
- Fabiola Paes LemeFLFabiola Paes Leme
- José Eduardo GonçalvesJGJosé Eduardo Gonçalves
- Lara Duque Estrada Meyer FagundesLFLara Duque Estrada Meyer Fagundes
- Natália FagundesNFNatália Fagundes
- Marcelo Pires Nogueira de CarvalhoMCMarcelo Pires Nogueira de Carvalho
- Suzane Lilian BeierSBSuzane Lilian Beier
Open Access
Abstract
Boa constrictor snakes represent a suitable model for studying the absorption, metabolism, and elimination of tramadol due to their distinct physiological characteristics. The objective of this work was to provide preliminary data on the pharmacokinetics of tramadol and its active metabolite, O-desmethyltramadol (M1), in the plasma of Boa constrictor using liquid chromatography with fluorescence detection. Ten snakes received tramadol (5 mg kg−1) both into the epaxial musculature (TRIM) and into the paravertebral vein (TRIV) with a 45-day interval between the two administration methods. Blood samples were taken at specified time points to analyze the pharmacokinetics. Data were evaluated with an independent pharmacokinetic model (R software version 4.3.0). A paired Student’s t-test was used for all parametric variables, except clearance, which was analyzed with the Wilcoxon test. A significance level of 5% was applied. The mean (range) maximum concentration of tramadol, volume of distribution, clearance, and elimination half-life for the TRIM group were 2.58 µg mL−1, 10.58 ± 2.91 L kg−1, 0.36 L kg−1 h−1, and 19.96 ± 8.34 h, respectively. For the TRIV group, these values were 3.39 µg mL−1, 5.60 ± 1.69 L kg−1, 0.22 L kg h−1, and 17.32 ± 7.55 h−1, respectively. M1 achieved maximum concentration and elimination half-lives of 0.58 µg mL−1 and 49.89 ± 10.8 h, respectively, for TRIM and 0.59 µg mL−1 and 35.66 ± 10.85 h for TRIV. The bioavailability of intramuscular tramadol was 61%, and M1 remained at similar concentrations for 20 min after tramadol administration in both treatments. Tramadol is rapidly biotransformed into M1 in Boa constrictors, maintaining high concentrations over an extended period. The pharmacokinetic characteristics, particularly the sustained plasma concentrations of M1, suggest potential for effective analgesia in the Boa constrictor. Furthermore, the intramuscular route provides the additional advantage of ease and practicality of administration.Keywords
Funding Information
- CAPES (Coordination for the Improvement of Higher Education Personnel)
- Graduate Collegiate of the School of Veterinary Medicine at UFMG
This publication has 16 references indexed in Scilit:
- Adjuvant Analgesics in Acute Pain ManagementVeterinary Clinics of North America: Small Animal Practice, 2019
- Revisiting Tramadol: A Multi-Modal Agent for Pain ManagementCNS Drugs, 2019
- Identification of canine cytochrome P‐450s (CYPs) metabolizing the tramadol (+)‐M1 and (+)‐M2 metabolites to the tramadol (+)‐M5 metabolite in dog liver microsomesJournal of Veterinary Pharmacology and Therapeutics, 2018
- Pain and Its Control in ReptilesVeterinary Clinics of North America: Exotic Animal Practice, 2018
- Review of Opioid Pharmacogenetics and Considerations for Pain ManagementPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2017
- Evidence for polymorphism in the cytochrome P450 2D50 gene in horsesJournal of Veterinary Pharmacology and Therapeutics, 2015
- Pharmacokinetic/pharmacodynamic assessments of 10 mg/kg tramadol intramuscular injection in yellow‐bellied slider turtles (Trachemys scripta scripta)Journal of Veterinary Pharmacology and Therapeutics, 2015
- Sample size calculationAllergologia et Immunopathologia, 2014
- Pharmacokinetics, intraoperative effect and postoperative analgesia of tramadol in catsResearch in Veterinary Science, 2011
- Pharmacogenetics of OpioidsClinical Pharmacology & Therapeutics, 2007